Literature DB >> 24115269

p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary.

Lanea M Keller1, Thomas J Galloway, Thomas Holdbrook, Karen Ruth, Donghua Yang, Cara Dubyk, Douglas Flieder, Miriam N Lango, Ranee Mehra, Barbara Burtness, John A Ridge.   

Abstract

BACKGROUND: The purpose of this study was to report associations between p16 status, clinicopathologic characteristics, and outcomes for head and neck squamous cell carcinoma of unknown primary (CUP).
METHODS: Specimens of squamous cell CUP were reanalyzed. Human papillomavirus (HPV) status was determined by p16 stain. A tissue microarray (TMA) was constructed to evaluate biomarkers potentially prognostic in head and neck squamous cell carcinoma (HNSCC).
RESULTS: A majority of the population (n = 26; 74%) was p16 positive (+). Prognostic factors benefiting survival were p16+ status (p < .0001), absence of macroscopic extracapsular extension (ECE; p = .004), younger age (p = .01), and higher grade (p = 0.007). The prognostic implication of worse overall survival (OS) with macroscopic ECE (p = .009) remained significant when limited to patients who were p16+ (p = .002). Exploratory TMA between unknown primary and controls suggested a biomolecular difference between squamous cell CUP and known-primary cancer.
CONCLUSION: The majority of patients with squamous cell CUP were p16+, indicative of HPV association. P16 staining and ECE seem to be the most prognostic features in squamous cell CUP.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  concurrent chemotherapy; extracapsular extension (ECE); human papillomavirus (HPV); tissue microarray; unknown primary

Mesh:

Substances:

Year:  2014        PMID: 24115269      PMCID: PMC3972378          DOI: 10.1002/hed.23514

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  32 in total

1.  Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study.

Authors:  D T Huang; C R Johnson; R Schmidt-Ullrich; M Grimes
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.

Authors:  Anthony McCabe; Marisa Dolled-Filhart; Robert L Camp; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2005-12-21       Impact factor: 13.506

3.  Diagnosis and management of carcinoma of unknown primary in the head and neck.

Authors:  Wolfgang J Issing; Behsad Taleban; Stefan Tauber
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-04-09       Impact factor: 2.503

4.  Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer.

Authors:  K K Ang; A Trotti; B W Brown; A S Garden; R L Foote; W H Morrison; F B Geara; D W Klotch; H Goepfert; L J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

Review 5.  Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?

Authors:  C Nieder; V Gregoire; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

6.  Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.

Authors:  Michelle L Klem; James G Mechalakos; Suzanne L Wolden; Michael J Zelefsky; Bhuvanesh Singh; Dennis Kraus; Ashok Shaha; Jatin Shah; David G Pfister; Nancy Y Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

7.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

Authors:  Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

8.  Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study.

Authors:  Jørgen Johansen; Simon Buus; Annika Loft; Susanne Keiding; Marie Overgaard; Hanne Sand Hansen; Cai Grau; Troels Bundgaard; Jørgen Kirkegaard; Jens Overgaard
Journal:  Head Neck       Date:  2008-04       Impact factor: 3.147

Review 9.  The unknown biology of the unknown primary tumour: a literature review.

Authors:  A J van de Wouw; R L H Jansen; E J M Speel; H F P Hillen
Journal:  Ann Oncol       Date:  2003-02       Impact factor: 32.976

10.  Association between p53 and human papillomavirus in head and neck cancer survival.

Authors:  Elaine M Smith; Donghong Wang; Linda M Rubenstein; William A Morris; Lubomir P Turek; Thomas H Haugen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

View more
  22 in total

1.  Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis.

Authors:  Müjdat Yildirim; Jens Müller von der Grün; Ria Winkelmann; Emmanouil Fokas; Franz Rödel; Hanns Ackermann; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2017-01-31       Impact factor: 3.621

2.  Patterns of failure in patients with head and neck carcinoma of unknown primary treated with radiation therapy.

Authors:  John Cuaron; Shyam Rao; Suzanne Wolden; Michael Zelefsky; Karen Schupak; Borys Mychalczak; Nancy Lee
Journal:  Head Neck       Date:  2015-07-06       Impact factor: 3.147

3.  Predictors of survival and recurrence after primary surgery for cervical metastasis of unknown primary.

Authors:  Won Ki Cho; Jong-Lyel Roh; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-19       Impact factor: 4.553

Review 4.  The prevalence of human papillomavirus in squamous cell carcinoma of unknown primary site metastatic to neck lymph nodes: a systematic review.

Authors:  Paolo Boscolo-Rizzo; Lea Schroeder; Salvatore Romeo; Michael Pawlita
Journal:  Clin Exp Metastasis       Date:  2015-09-10       Impact factor: 5.150

Review 5.  Critical Changes in the Staging of Head and Neck Cancer.

Authors:  Christine M Glastonbury
Journal:  Radiol Imaging Cancer       Date:  2020-01-31

6.  Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival.

Authors:  Miloslav Pala; Pavla Novakova; Zdena Pechacova; Lucie Vesela; Antonin Vrana; Jarmila Sukova; Petra Holeckova; Tereza Drbohlavova; Tomas Podlesak; Lubos Petruzelka
Journal:  Strahlenther Onkol       Date:  2022-08-09       Impact factor: 4.033

7.  Factors Influencing the Outcome of Head and Neck Cancer of Unknown Primary (HNCUP).

Authors:  Matthias Balk; Robin Rupp; Konstantinos Mantsopoulos; Matti Sievert; Magdalena Gostian; Moritz Allner; Philipp Grundtner; Markus Eckstein; Heinrich Iro; Markus Hecht; Antoniu-Oreste Gostian
Journal:  J Clin Med       Date:  2022-05-10       Impact factor: 4.964

8.  The Added Value of 68Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG-Negative Findings.

Authors:  Bingxin Gu; Xiaoping Xu; Ji Zhang; Xiaomin Ou; Zuguang Xia; Qing Guan; Silong Hu; Zhongyi Yang; Shaoli Song
Journal:  J Nucl Med       Date:  2021-09-30       Impact factor: 11.082

9.  Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: role of elective irradiation.

Authors:  Primož Strojan; Marko Kokalj; Vesna Zadnik; Aleksandar Aničin; Gaber Plavc; Vojislav Didanović; Robert Šifrer; Boštjan Lanišnik
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-30       Impact factor: 2.503

10.  Patterns of care analysis for head & neck cancer of unknown primary site: a survey inside the German society of radiation oncology (DEGRO).

Authors:  Jens Müller von der Grün; Dimitra Bon; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2018-05-14       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.